

BETAGLUE TECHNOLOGIES STRENGTHEN ITS EXPERTISE IN STRATEGIC AREAS WITH FOUR NEW MANAGERS

- *Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas*
- *Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated*

Milan, October 19, 2022 - **BetaGlue Technologies**, a highly innovative company working in the Life Sciences sector, announces the **appointment of four new managers**, strengthening the team across strategic areas for its business development.

Betty Polikar, Gianluca Danieli, Pietro Bubba Bello, and Gaia Bisaccioni joined the company in September in the Clinical Research, Manufacturing, and Quality areas.

Betty Polikar was Head of the Startup Unit of the Center of Excellence at “Bambino Gesù” Children’s Hospital in Rome and will now bring her experience as **Head of Clinical Operations of BetaGlue**.

Gianluca De Danieli is taking on the role of **Head of Clinical Development**, **Pietro Bubba Bello** will be **Head of Manufacturing & Operations**, and **Gaia Bisaccioni** is joining the company as **Head of Quality**. The three managers join the company from Novartis, after having worked at Advanced Accelerator Applications (AAA), a company that has pioneered the nuclear medicine revolution, following its recent €3.9 billion acquisition.

At the same time, clinical progresses are ongoing for **BAT-90**, the advanced cancer radiotherapy platform developed by BetaGlue: on September 29, 2022, **the first breast cancer patient was treated** at New Hospitals in Tblisi, Georgia. This is the second “first in man” clinical trial, after the one in liver cancer patients (hepatocarcinoma, please see the July 11, 2022 press release¹).

Such developments were also made possible by the successful closing of the €10 million equity financing round by Fin Posillipo (Petroni Group), Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaolo Group), Profequycapital and Romed, with a reinvestment from existing investors Innogest Capital and Panakès Partners (please see press release of July 19, 2022²).

Riccardo Palmisano, Executive Chairman, and Antonino Amato, CEO/CMO of BetaGlue Technologies, declared: *“The appointment of four new highly skilled leaders with proven experience in Life Sciences’ key areas, along with the increased financial assets stemming from the successful closing of our recent financing round, enables BetaGlue to continue with confidence toward achieving the ambitious goal of creating value for both Patients and Shareholders”.*

*** **

¹ “BetaGlue takes radiotherapy inside solid tumours: first patient treated with BAT-90”, https://www.betaglue.com/wp-content/uploads/2022/07/20220711_CS_BetaGlue_FirstPatientBat90.pdf.

² “BetaGlue Technologies: closing of a EUR 10 million financing round”, https://www.betaglue.com/wp-content/uploads/2022/07/20220719_CS_BetaGlue_FinancingRound.pdf.



BetaGlue Technologies SpA

BetaGlue Technologies is a highly innovative company working in the Life Sciences sector. The Company has developed BAT-90, an advanced radiotherapy platform targeting inoperable solid tumours and/or surgical resection margins. BetaGlue enjoys the support of a highly qualified Scientific Advisory Board, as well as of leading national and international advisers, in the development of its solutions.

Web site: www.betaglue.com

LinkedIn: www.linkedin.com/company/betaglue-technologies

Mail: info@betaglue.com

Media contacts

Community - Reputation Advisers

betaglue@community.it

Giuliano Pasini

Federico Nascimben | +39 351 1059957

Giulia Vaccaro | + 39 342 0865017